WO2022170732A1 - 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用 - Google Patents

一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用 Download PDF

Info

Publication number
WO2022170732A1
WO2022170732A1 PCT/CN2021/105637 CN2021105637W WO2022170732A1 WO 2022170732 A1 WO2022170732 A1 WO 2022170732A1 CN 2021105637 W CN2021105637 W CN 2021105637W WO 2022170732 A1 WO2022170732 A1 WO 2022170732A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
integer
replaced
och
Prior art date
Application number
PCT/CN2021/105637
Other languages
English (en)
French (fr)
Inventor
陈小元
徐鹏飞
郭志德
吴晓明
杨清宝
何田
Original Assignee
上海蓝纳成生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202110182478.0A external-priority patent/CN114369084B/zh
Priority claimed from CN202110753794.9A external-priority patent/CN113582975A/zh
Application filed by 上海蓝纳成生物技术有限公司 filed Critical 上海蓝纳成生物技术有限公司
Priority to CA3210863A priority Critical patent/CA3210863A1/en
Priority to JP2023531665A priority patent/JP2023545213A/ja
Priority to CN202180096379.9A priority patent/CN117120428A/zh
Priority to AU2021427618A priority patent/AU2021427618B2/en
Priority to EP21925385.3A priority patent/EP4227300A4/en
Priority to US18/257,063 priority patent/US11975079B2/en
Priority to KR1020237014883A priority patent/KR102648429B1/ko
Publication of WO2022170732A1 publication Critical patent/WO2022170732A1/zh
Priority to ZA2023/08458A priority patent/ZA202308458B/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to the field of nuclear medicine and molecular imaging, in particular to a truncated Evans blue-modified fibroblast activation protein inhibitor and its preparation labeling and application.
  • Fibroblast activation protein is a membrane serine peptidase that is expressed on the surface of activated fibroblasts in the tumor stroma and plays an important role in the occurrence and development of tumors.
  • FAP Fibroblast activation protein
  • Previous studies have shown that FAP is generally not expressed in normal human tissues, but is selectively highly expressed on the surface of stromal fibroblasts in more than 90% of epithelial malignant tumors, including breast cancer, ovarian cancer, lung cancer, colorectal cancer, gastric cancer and Pancreatic cancer, etc. Given its extensive expression and important role in tumors, FAP has become an important target for tumor imaging and therapy.
  • radionuclide-labeled fibroblast activation protein inhibitor represented by quinolinic acid derivatives
  • FAPI radionuclide-labeled fibroblast activation protein inhibitor
  • PET/CT imaging agents such as FAPI-02 and FAPI-04 have achieved more than 30 different types of tumor-specific imaging.
  • FAPI imaging has a lower background in the brain, liver and oropharyngeal mucosa, and has a higher detection rate for tumor lesions.
  • the FAPIs reported so far are rapidly cleared from the blood circulation while being rapidly eluted at the tumor site. This metabolic property is beneficial for imaging because it provides a cleaner background.
  • the primary purpose of the present invention is to develop a truncated Evans blue (tEB) and fibroblast activation protein inhibitor (FAPI) linker, which is characterized by the combination of truncated Evans blue and serum albumin Effective binding enables albumin as a FAPI delivery vehicle, thereby prolonging its half-life in peripheral blood and improving uptake, enrichment and retention time in tumors.
  • the tEB-FAPI linker developed by the invention can overcome the defects of too fast metabolism of small molecule FAPI and too short retention time of target organs, improve the effect of targeted FAP protein nuclide therapy and imaging, and has the potential of clinical application.
  • Another object of the present invention is to provide a class of radiolabeled truncated Evans blue-modified fibroblast activation protein inhibitors (tEB-FAPI) with long circulating half-life;
  • Another object of the present invention is to provide a method for preparing the radiolabeled tEB-FAPI complex
  • Another object of the present invention is to provide the application of the complex in tumor radionuclide imaging and therapy targeting FAP protein.
  • the technical solution to achieve the above-mentioned primary object of the present invention includes the following two aspects: ligand synthesis and radiolabeling.
  • the present invention provides a truncated Evans blue (tEB)-modified fibroblast activation protein inhibitor (FAPI), the compound structure is shown in the following formula (I), denoted as "tEB-FAPI" ";
  • L 1 is a lysine or glutamic acid structure, or a derivative compound structure containing a lysine or glutamic acid structure;
  • L 2 is -(CH 2 ) n -, where n is an integer from 0 to 30, wherein each CH 2 may be individually or not -O-, -NH-, -(CO)-, -NH(CO) - or -(CO)-NH- substitution, provided that no two adjacent CH 2 groups are substituted;
  • L 3 is -(CH 2 ) m -, where m is an integer from 0 to 30, wherein each CH 2 may be individually replaced with or without -O- or -(CO)-, provided that there are no two phases The adjacent CH 2 group is replaced;
  • L 4 is -(CH 2 ) p -, where p is an integer from 0 to 30, where each CH 2 may be individually or not -O-, -NH-, -(CO)-, -NH(CO) - or -(CO)-NH- substitution, provided that no two adjacent CH 2 groups are substituted;
  • X is selected from N, C, O, S or any one of the following structures:
  • R1 is the following structure from fibroblast activation protein inhibitor :
  • R 2 is a nuclide chelating group selected from any of the following structures:
  • R 3 -R 4 are the same or different, and are independently selected from H or F.
  • L 2 in the formula (I) is -(CH 2 ) n -; n is an integer of 0-16, more preferably an integer of 0-12, further preferably 0, 3 or 10 ; wherein each -CH2- may be individually replaced with or without -O-, -NH- or -(CO)-, provided that no two adjacent -CH2- groups are replaced.
  • L 3 in the formula (I) is -(CH 2 ) m -; m is an integer of 0-20, more preferably an integer of 1-6, further preferably 2 or 3; wherein Each -CH2- may be individually replaced with or without -O-, provided that no two adjacent -CH2- groups are replaced.
  • L 4 in the formula (I) is -(CH 2 ) p -; p is an integer of 0-20, more preferably an integer of 0-12, further preferably 3, 4, and 9 or 12, most preferably 3; wherein each -CH2- may be independently replaced with or without -O-, -NH-, -(CO)-, -NH(CO)- or -(CO)-NH-, A condition for substitution is that no two adjacent -CH2- groups are replaced.
  • X in the formula (I) is L 3 is -(CH 2 ) 3 -, L 4 is -(CH 2 ) 0 -, and R 2 is DOTA, that is, a preferred compound of the present invention, tEB-FAPI, whose structure is shown in the following formula II:
  • L 1 is glutamic acid or lysine structure
  • L 2 is -(CH 2 ) 0 , -NH-CH 2 -(CO)-, -NH -CH 2 -(CH 2 OCH 2 ) 2 -CH 2 -(CO)-, -NH-CH 2 -(CH 2 OCH 2 ) 4 -CH 2 (CO)-, -(CO)-CH 2 -( CO)-, -(CO)-(CH 2 ) 2 -(CO)-, -(CO)-CH 2 -(CH 2 OCH 2 ) 2 -CH 2 (CO)- or -(CO)-CH 2 -(CH 2 OCH 2 ) 4 -CH 2 (CO)-.
  • L 1 is a glutamic acid structure
  • L 2 is -(CH 2 ) 0 -, -NH-CH 2 -(CO)-, -NH-CH 2 -(CH 2 OCH 2 ) 2 -CH 2 -(CO) - or -NH-CH 2 -(CH 2 OCH 2 ) 4 -CH 2 (CO)-
  • L 3 is -(CH 2 ) 3 -
  • L 4 is -(CH 2 ) 0 -
  • R 2 is DOTA
  • R 3 and R 4 are both H or both are F atoms.
  • L 1 is a lysine structure
  • L 2 is -(CO)-CH 2 --(CO)-, -(CO)-(CH 2 ) 2 -(CO)-, -(CO)-CH 2 -( CH 2 OCH 2 ) 2 -CH 2 (CO)- or -(CO)-CH 2 -(CH 2 OCH 2 ) 4 -CH 2 (CO)-
  • L 3 is -(CH 2 ) 3 -
  • L 4 It is -(CH 2 ) 0 -
  • R 2 is DOTA
  • R 3 and R 4 are both H or F atoms.
  • the structure of the compound tEB-FAPI is any one of the following formulas (II-1) to (II-16):
  • the present invention further provides a method for preparing the compound tEB-FAPI represented by formula (II-1), comprising the following steps:
  • the preferred method of the present invention for preparing the compound tEB-FAPI represented by formula (II-1) specifically includes the following steps:
  • 6-Hydroxy-4-quinoline carboxylic acid (compound 1) and tert-butyl glycine were dissolved in N,N-dimethylformamide, and HATU was added to obtain compound 2; compound 2 was dissolved in N,N-dimethylformamide In methylformamide, add 1-bromo-3 chloropropane and potassium carbonate, heat the reaction system to 60 °C for a certain period of time to obtain compound 3; dissolve compound 3 in N,N-dimethylformamide, add 1 -tert-butoxycarbonylpiperazine and potassium iodide react to obtain compound 4; compound 4 is dissolved in trifluoroacetic acid solution to remove the protective group to obtain compound 5; compound 5 is dissolved in N,N-dimethylformamide, Add di-tert-butyl dicarbonate and acid binding agent to obtain compound 6; compound 6 and (S)-pyrrolidine-2-carbonitrile hydrochloride undergo condensation reaction under the action of HATU and DIPEA to obtain compound 7;
  • the preparation method of other tEB-FAPI compounds in the scheme of the present invention is similar to the preparation method of compound 20, and can basically be prepared by referring to the synthetic route of compound 20 based on the existing conventional means.
  • the present invention further provides a radiolabeled tEB-FAPI complex, which is a complex obtained by labeling the radionuclide with the compound of formula (I) described in the present invention as a ligand.
  • the radiolabeled complex can be used as a novel tumor radioactive diagnosis and treatment probe, that is, as a radionuclide diagnostic probe or a radionuclide therapeutic probe.
  • the nuclide can be selected from 177 Lu, 90 Y, 18 F, 64 Cu, 68 Ga, 62 Cu, 67 Cu, 86 Y, 89 Zr, 99m Tc, 89 Sr, 153 Sm, 149 Tb, 161 Tb, 186 Any one of Re, 188 Re, 212 Pb, 213 Bi, 223 Ra, 225 Ac, 226 Th, 227 Th, 131 I, 211 At or 111 In; preferably 68 Ga, 177 Lu or 90 Y.
  • the preferred complex of the present invention has the structure shown in the following formula (IV):
  • L 1 is a lysine or glutamic acid structure, or a derivative compound structure containing a lysine or glutamic acid structure;
  • L 2 is -(CH 2 ) n -, where n is an integer from 0 to 30, wherein each CH 2 may be individually or not -O-, -NH-, -(CO)-, -NH(CO) - or -(CO)-NH- substitution, provided that no two adjacent CH 2 groups are substituted;
  • L 3 is -(CH 2 ) m -, where m is an integer from 0 to 30, wherein each CH 2 may be individually replaced with or without -O- or -(CO)-, provided that there are no two phases The adjacent CH 2 group is replaced;
  • X is selected from N, C, O, S or the following structures:
  • R 3 and R 4 are the same or different, and are independently selected from H or F;
  • M is a radionuclide, selected from any one of 68 Ga, 177 Lu or 90 Y.
  • L 2 in the formula (IV) is -(CH 2 ) n -; n is an integer of 0-16, more preferably an integer of 0-12, further preferably 0, 3 or 10; wherein each -CH2- may be individually replaced with or without -O-, -NH- or -(CO)-, provided that no two adjacent -CH2- groups are replaced.
  • More preferred L 2 is -(CH 2 ) 0 , -NH-CH 2 -(CO)-, -NH-CH 2 -(CH 2 OCH 2 ) 2 -CH 2 -(CO)-, -NH-CH 2 -(CH 2 OCH 2 ) 4 -CH 2 (CO)-, -(CO)-CH 2 -(CO)-, -(CO)-(CH 2 ) 2 -(CO)-, -(CO) -CH2- ( CH2OCH2 ) 2 - CH2 (CO)- or -(CO) -CH2- ( CH2OCH2 ) 4 - CH2 ( CO)-.
  • L 3 in the formula (IV) is -(CH 2 ) m -; m is an integer of 0-20, more preferably an integer of 1-6, further preferably 2 or 3 ; wherein each -CH2- may be individually replaced with or without -O-, provided that no two adjacent -CH2- groups are replaced. More preferred L 3 is -(CH 2 ) 3 -.
  • the radiolabeled complex of the present invention can be prepared by the compound containing a radionuclide and the compound of formula (I) of the present invention according to various existing labeling methods; the preferred labeling method of the present invention is the following wet method or freeze-drying method:
  • the wet labeling scheme includes: dissolving an appropriate amount of the compound of formula (I) according to the present invention in a buffer solution or deionized water; adding a radionuclide solution to the obtained solution, and performing a closed reaction for 5-40 minutes to generate a radionuclide label the complex;
  • the lyophilization labeling scheme includes: dissolving an appropriate amount of the compound of formula (I) of the present invention in a buffer solution or deionized water; after sterile filtration, the obtained solution is divided into containers, and after freeze-drying Stoppered and sealed to obtain a freeze-dried kit; add an appropriate amount of acetic acid solution or buffer solution to the freeze-dried kit to dissolve, then add the corresponding radionuclide solution, and seal the reaction for 5-40 minutes to generate a radionuclide-labeled complex .
  • the said repacking container is preferably a cryopreservation tube or a controlled antibiotic bottle.
  • excipients such as mannitol, ascorbic acid, etc.
  • the kit is made. Forming is optimal.
  • the products obtained from the wet labeling scheme and the freeze-drying labeling scheme can be further prepared by conventional treatments (such as chromatographic separation and purification, rotary evaporation to remove the solvent, dissolving the residue with PBS or water or physiological saline, sterile filtration, etc.). into injection.
  • conventional treatments such as chromatographic separation and purification, rotary evaporation to remove the solvent, dissolving the residue with PBS or water or physiological saline, sterile filtration, etc.
  • a preferred preparation method of radiolabeled compound 20 is a wet labeling method, which includes the following steps: compound 20 was dissolved in buffer solution or deionized water; fresh radioactive solution was added to it, reacted at 37-90°C for 5-40min, and cooled; after diluting the reaction solution with water, it was separated and purified by Sep-Pak C18 chromatographic column.
  • Another preferred preparation method of the radiolabeled compound 20 of the present invention is the freeze-drying labeling method, which includes: dissolving the compound 20 and other necessary reagents in a buffer, and the obtained solution is sterile filtered and then packed into cryovials , freeze-dried and sealed to obtain a freeze-dried kit; add an appropriate amount of buffer solution to the freeze-dried kit to dissolve, then add a freshly prepared radioactive solution, seal it at 37-120 ° C for 5-40 min, and cool; add water to dilute the reaction solution, Sep-Pak C18 chromatographic column separation and purification, rinse the chromatographic column with buffer or water to remove unreacted radioactive ions, rinse with hydrochloric acid ethanol solution or ethanol solution, and then dilute with normal saline or PBS and sterile filter to obtain the structure.
  • the injection solution of the radiolabeled complex represented by formula (IV-1); wherein the radionuclide M is 68 Ga, 177 Lu or 90 Y and the like.
  • the buffer solution is a substance that stabilizes the pH value of the reaction solution, and can be acetate, lactate, tartrate, malate, maleate, succinate, ascorbate, carbonate and phosphate, and mixtures of them, etc.
  • the present invention also provides the use of the tEB-FAPI compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a radionuclide therapy or imaging drug for tumors with high FAP protein expression.
  • the present invention also provides the application of the radiolabeled tEB-FAPI complex represented by formula (IV) in radionuclide therapy and imaging of tumors with high FAP protein expression.
  • the complex is prepared into an injection, which is administered by intravenous injection for patients with tumors with high FAP protein expression.
  • the tumors with high FAP protein expression include but are not limited to breast cancer, ovarian cancer, lung cancer, colorectal cancer, gastric cancer or pancreatic cancer.
  • the invention provides a truncated Evans blue-modified fibroblast activation protein inhibitor tEB-FAPI and its radionuclide-labeled complex, as well as a preparation method and labeling method of the compound.
  • Biological test results show that it has significantly prolonged blood circulation half-life, enhanced tumor uptake enrichment and retention time. This novel performance is not present in other FAPI imaging agents, and it is suitable for radionuclide therapy and imaging of tumors with high FAP protein expression.
  • Fig. 1 is a mass spectrum of compound 2 in Example 1 of the present invention.
  • FIG. 2 is the hydrogen nuclear magnetic spectrum of Compound 2 in Example 1 of the present invention.
  • Figure 3 is the carbon nuclear magnetic spectrum of Compound 2 in Example 1 of the present invention.
  • FIG. 4 is a mass spectrum of Compound 3 in Example 1 of the present invention.
  • FIG. 5 is the hydrogen nuclear magnetic spectrum of Compound 3 in Example 1 of the present invention.
  • FIG. 6 is a mass spectrum of Compound 4 in Example 1 of the present invention.
  • FIG. 7 is the hydrogen nuclear magnetic spectrum of Compound 4 in Example 1 of the present invention.
  • Figure 8 is the carbon nuclear magnetic spectrum of Compound 4 in Example 1 of the present invention.
  • FIG. 9 is a mass spectrum of Compound 7 in Example 1 of the present invention.
  • FIG. 10 is the hydrogen nuclear magnetic spectrum of Compound 7 in Example 1 of the present invention.
  • Fig. 11 is the carbon nuclear magnetic spectrum of Compound 7 in Example 1 of the present invention.
  • FIG. 12 is a mass spectrum of Compound 10 in Example 1 of the present invention.
  • FIG. 13 is a mass spectrum of Compound 20 in Example 1 of the present invention.
  • Figure 14 is a mass spectrum of the compound in Example 10 of the present invention.
  • Figure 15 is a mass spectrum of the compound in Example 11 of the present invention.
  • Figure 16 is the HPLC chromatogram of Compound 10 in Example 1 of the present invention.
  • Figure 17 is the HPLC chromatogram of Compound 17 in Example 1 of the present invention.
  • Figure 19 is the HPLC chromatogram of Compound 19 in Example 1 of the present invention.
  • Figure 20 is the HPLC chromatogram of the reaction system of Compound 19 and DOTA-NHS in Example 1 of the present invention.
  • Figure 21A and Figure 21B show the MicroPET imaging of 68Ga-labeled tEB-FAPI complex and 68Ga-labeled FAPI-02 in normal mice in the present invention.
  • Figure 22 shows the SPECT imaging of 177Lu-tEB-FAPI prepared in Example 40 of the present invention in normal mice at different time points.
  • Figure 23 shows the SPECT imaging of 177Lu-tEB-FAPI prepared in Example 40 of the present invention in human pancreatic cancer xenograft model mice at different time points.
  • compound 3 (0.76 g, 2.0 mmol), 1-tert-butoxycarbonylpiperazine (0.55 g, 3.0 mmol), and potassium iodide (0.49 g, 3.0 mmol) were sequentially added to 30 mL of acetonitrile.
  • compound 4 (0.52 g, 1.0 mmol) was dissolved in 10 mL of a mixed solution of dichloromethane and trifluoroacetic acid (volume ratio 9:1), the system was warmed to room temperature and reacted for 2 h. After the reaction, the pressure was reduced. The solvent was distilled off, dissolved in 10 mL of N,N-dimethylformamide, and used for later use.
  • FIG. 12 is the mass spectrum of compound 10.
  • FIG. 12 is the mass spectrum of compound 10.
  • De-tert-butyl ester and Boc protection were performed using thioanisole:1,2-ethanedithiol:anisole:TFA (5:3:2:90) at room temperature. After the reaction was completed, TFA was removed by argon flow, followed by dissolving with 10 mL of N,N-dimethylformamide for use.
  • Examples 2-16 are respectively shown in formula (II-2) to formula (II-16), and their preparation methods can be referred to in Example 1, and the glutamic acid structure reacted with compound 14 is replaced by Lysine structure, or replace 5,8,11,14-tetraoxa-2-azaheptadecadioic acid-1-tert-butyl ester reacted with compound 8 with 5,8,11-trioxa -1-tert-butyl 2-azatridecanedioic acid, tert-butyl 9-amino-4,7-dioxanonanoate, tert-butyl glycine or other suitable compounds, or will react with compound 6 (S)-pyrrolidine-2-carbonitrile hydrochloride is replaced with 3,3-difluoropyrrolidine hydrochloride, or both, to obtain the following corresponding structures:
  • Example 10 The mass spectrum of the compound (II-10) in Example 10 is shown in FIG. 14 ; the mass spectrum of the compound in Example 11 (II-11) is shown in FIG. 15 .
  • the unlabeled 68 Ga ions were removed with 10 mL of water, and then eluted with 0.3 mL of 10 mM HCl in ethanol to obtain the 68 Ga-labeled tEB-FAPI complex. .
  • the eluate was diluted with physiological saline and sterile filtered to obtain an injection of 68 Ga-labeled tEB-FAPI complex.
  • Freeze-drying method add about 18.5-1850 megabecquerel (MBq) 68 GaCl 3 hydrochloric acid solution (eluted from a germanium-gallium generator) into a freeze-dried kit containing compound 20, and react at 37° C. for 20 min after mixing. Take a C18 separation column, rinse slowly with 10 mL of absolute ethanol, and then rinse with 10 mL of water. After diluting the labeling solution with 10 mL of water, the sample was loaded onto the separation column. First, the unlabeled 68 Ga ions were removed with 10 mL of water, and then eluted with 0.3 mL of 10 mM HCl in ethanol to obtain the complex eluent. The eluate was diluted with physiological saline and sterile filtered to obtain an injection of 68 Ga-labeled tEB-FAPI complex.
  • Mq megabecquerel
  • the unlabeled 177 Lu ions were removed with 10 mL of water, and then eluted with 0.3 mL of 10 mM HCl in ethanol to obtain three 177 Lu-labeled tEB-FAPI. complex.
  • the eluate was diluted with physiological saline and sterile filtered to obtain three injections of 177Lu -labeled tEB-FAPI complexes.
  • Freeze-drying method about 18.5-1850MBq 177 LuCl 3 sodium acetate solution was added to three freeze-dried solutions containing Compound 20 of Example 1, Example 2 (compound of formula II-2) and Example 3 (compound of Formula II-3), respectively.
  • a dry kit mix and react at 90°C for 20min. Take a C18 separation column, rinse slowly with 10 mL of absolute ethanol, and then rinse with 10 mL of water. After diluting the labeling solution with 10 mL of water, the sample was loaded onto the separation column.
  • the unlabeled 177 Lu ions were removed with 10 mL of water, and then eluted with 0.3 mL of 10 mM HCl in ethanol to obtain three 77 Lu-labeled tEB-FAPI.
  • Complex eluent The eluate was diluted with physiological saline and sterile filtered to obtain three injections of 177Lu -labeled tEB-FAPI complexes.
  • the HPLC system was as follows: SHIMADZULC-20A; C18 column (YMC, 3 ⁇ m, 4.6 ⁇ 150 mm) was used for analysis. Detection wavelength 254nm, flow rate 1mL/min, elution gradient: 0-3 minutes: 10% acetonitrile 0 and 90% water (50mM ammonium acetate) remain unchanged; 3-16 minutes: increase to 90% acetonitrile and 10% water (50 mM ammonium acetate); 16-18min: hold 90% acetonitrile and 10% water (50 mM ammonium acetate); 18-20min: reduce to 10% acetonitrile and 90% water (50 mM ammonium acetate); 20-22min: hold 10% Acetonitrile and 90% water (50 mM ammonium acetate).
  • 68Ga-tEB-FAPI with a purity of more than 95% was prepared.
  • 3.7MBq of 68Ga -tEB- FAPI or 68Ga -FAPI-02 (as a control) was injected through the tail vein.
  • MicroPET imaging was performed at 0-120 min after administration, respectively. The results are shown in Figure 21A and Figure 21B.
  • 177Lu -tEB-FAPI (based on Compound 20 in Example 1) with a purity greater than 95% was prepared according to the method of Example 40, and injected into normal mice and human pancreatic cancer xenograft model mice via tail vein respectively 1.3MBq of 177Lu -tEB-FAPI.
  • SPECT imaging was performed at different time points after injection. The SPECT imaging results of normal mice are shown in Figure 22, and the SPECT imaging results of human pancreatic cancer xenograft model mice are shown in Figure 23.
  • the modified fibroblastin inhibitor of truncated Evans blue provided by the present invention can significantly prolong its circulating half-life, and can enhance tumor uptake, enrichment and retention time. Imaging agents do not have. It has been confirmed by further preclinical animal level and clinical studies, and it is expected to become the radionuclide therapy and imaging of tumors with high FAP protein expression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂化合物，由连接基团L 1、L 2、L 3、L 4和X将截短型伊文思蓝、成纤维细胞活化蛋白抑制剂和核素螯合基团连接在一起构成，其结构如式(I)。所述化合物及该化合物结构的放射性标记物具有显著延长的血液循环半衰期、增强的肿瘤摄取富集和保留时间，适合用作FAP蛋白高表达肿瘤的核素治疗和显像。

Description

一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用 技术领域
本发明涉及核医学与分子影像学领域，具体地涉及一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备标记和应用。
背景技术
成纤维细胞活化蛋白(Fibroblast activation protein，FAP)是一种膜丝氨酸肽酶，表达于肿瘤间质活化的成纤维细胞表面，在肿瘤的发生发展过程中发挥重要作用。既往研究表明，FAP在正常人组织中一般无表达，但是选择性地高表达于90％以上的上皮恶性肿瘤的基质成纤维细胞表面，包括乳腺癌、卵巢癌、肺癌、结直肠癌、胃癌和胰腺癌等。鉴于其在肿瘤中的广泛表达及重要作用，FAP已成为肿瘤显像和治疗的重要靶点。
目前，放射性核素标记的以喹啉酸衍生物为代表的成纤维细胞活化蛋白抑制剂(FAPI)已在肿瘤精准成像领域取得了重要进展。例如，FAPI-02和FAPI-04等PET/CT显像剂已实现30余种不同类型的肿瘤特异性显像。与FDG显像相比，FAPI显像在脑、肝脏及口咽粘膜具有更低本底，对于肿瘤病灶有更高的检出率。目前报道的FAPI在血液循环中被快速清除，同时在肿瘤部位被快速洗脱。这种代谢特性对于显像是有益的，因为可以提供较为干净的背景。但对于治疗而言却十分不利，因为快速代谢和洗脱导致肿瘤部位有效剂量较低、保留时间过短，需要使用高剂量或更频繁的给药方式以满足治疗需求，增加了不良反应的可能性。
以FAPI-02为例，其在一个小时内便从血液循环中被完全清除，经过24h后在肿瘤部位保留剂量下降约75％。虽然最近的研究工作对FAPI结构中非药效团部分进行了优化，但对FAPI的肿瘤摄取剂量和保留时间的改善十分有限，不能满足治疗用途的需要。本领域普通技术人员可知，如果小分子药物在血管中循环时间过短或被机体快速清除，将造成药物与靶标结合不充分。因此，在制备FAPI探针时，如能适当延长探针的循环半衰期，将有可能提高探针在靶部位的摄取剂量和保留时间。
因此，需要新的策略来延长FAPI探针的循环半衰期，使其具有适宜的代谢动力学、较高的肿瘤摄取剂量和较长的肿瘤保留时间，满足核素治疗和显像需求。
发明内容
基于上述背景，本发明的首要目的在于开发一种截短型伊文思蓝(tEB)与成纤维细胞活化蛋白抑制剂(FAPI)连接物，其特点为通过截短型伊文思蓝与血清白蛋白有效结合，实现白蛋白作为FAPI递送载体，从而延长其在外周血中的半衰期，提高在肿瘤中的摄取富集和保留时间。本发明开发的tEB-FAPI连接物能够克服了小分子FAPI代谢过快以及靶器官保留时间过短的缺陷，改善靶向FAP蛋白核素治疗和显像效果，具有在临床上推广应用的潜力。
本发明的另一个目的在于提供一类具有长循环半衰期的放射性标记的截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂(tEB-FAPI)；
本发明的另一目的在于提供所述放射性标记的tEB-FAPI配合物的制备方法；
本发明的再一目的是提供所述的配合物在靶向FAP蛋白肿瘤核素显像和治疗中的应用。
实现本发明上述首要目的技术方案有以下配体合成和放射性标记两个方面。
第一方面，本发明提供一种截短型伊文思蓝(tEB)修饰的成纤维细胞活化蛋白抑制剂(FAPI)，所述 的化合物结构如下式(I)所示，记作“tEB-FAPI”；
Figure PCTCN2021105637-appb-000001
其中：
L 1为赖氨酸或谷氨酸结构，或含有赖氨酸或谷氨酸结构的衍生化合物结构；
L 2是-(CH 2) n-，其中n是0至30的整数，其中每个CH 2可以单独地用或不用-O-、-NH-、-(CO)-、-NH(CO)-或-(CO)-NH-替换，替换的条件是没有两个相邻的CH 2基团被替换；
L 3是-(CH 2) m-，其中m是0至30的整数，其中每个CH 2可以单独地用或不用-O-或-(CO)-替换，替换的条件是没有两个相邻的CH 2基团被替换；
L 4是-(CH 2) p-，其中p是0至30的整数，其中每个CH 2可以单独地用或不用-O-、-NH-、-(CO)-、-NH(CO)-或-(CO)-NH-替换，替换的条件是没有两个相邻的CH 2基团被替换；
X选自N、C、O、S或者以下结构中的任意一种：
Figure PCTCN2021105637-appb-000002
R 1为以下来自成纤维细胞活化蛋白抑制剂的结构：
Figure PCTCN2021105637-appb-000003
R 2是核素螯合基团，选自以下任意一种结构：
Figure PCTCN2021105637-appb-000004
R 3-R 4相同或不同，均独立的选自H或F。
本发明优选的方案中，所述式(I)中的L 2是-(CH 2) n-；n是0-16的整数，更优选是0-12的整数，进一步优选0、3或10；其中每个-CH 2-可以单独地用或不用-O-、-NH-或-(CO)-替换，替换的条件是没有两个相邻的-CH 2-基团被替换。
本发明优选的方案中，所述式(I)中的L 3是-(CH 2) m-；m是0-20的整数，更优选是1-6的整数，进一步优选2或3；其中每个-CH 2-可以单独地用或不用-O-替换，替换的条件是没有两个相邻的-CH 2-基团被替换。
本发明优选的方案中，所述式(I)中的L 4是-(CH 2) p-；p是0-20的整数，更优选是0-12的整数，进一步优选3、4、9或12，最优选3；其中每个-CH 2-可以单独地用或不用-O-、-NH-、-(CO)-、-NH(CO)-或-(CO)-NH-替换，替换的条件是没有两个相邻的-CH 2-基团被替换。
本发明优选的一种实施方式中，所述式(I)中的X为
Figure PCTCN2021105637-appb-000005
L 3为-(CH 2) 3-，L 4为-(CH 2) 0-，R 2为DOTA，即本发明优选的一种化合物tEB-FAPI，结构如下式II所示：
Figure PCTCN2021105637-appb-000006
其中R 3和R 4同为H或者同为F原子，L 1为谷氨酸或赖氨酸结构，L 2为-(CH 2) 0、-NH-CH 2-(CO)-、-NH-CH 2-(CH 2OCH 2) 2-CH 2-(CO)-、-NH-CH 2-(CH 2OCH 2) 4-CH 2(CO)-、-(CO)-CH 2-(CO)-、-(CO)-(CH 2) 2-(CO)-、-(CO)-CH 2-(CH 2OCH 2) 2-CH 2(CO)-或-(CO)-CH 2-(CH 2OCH 2) 4-CH 2(CO)-。
本发明更优选的一种实施方式中，所述式(I)中的X为
Figure PCTCN2021105637-appb-000007
L 1为谷氨酸结构，L 2为-(CH 2) 0-、-NH-CH 2-(CO)-、-NH-CH 2-(CH 2OCH 2) 2-CH 2-(CO)-或-NH-CH 2-(CH 2OCH 2) 4-CH 2(CO)-，L 3为-(CH 2) 3-，L 4为-(CH 2) 0-，R 2为DOTA，R 3和R 4同为H或者同为F原子。
本发明更优选的另一种实施方式中，所述式(I)中的X为
Figure PCTCN2021105637-appb-000008
L 1为赖氨酸结构，L 2为-(CO)-CH 2--(CO)-、-(CO)-(CH 2) 2-(CO)-、-(CO)-CH 2-(CH 2OCH 2) 2-CH 2(CO)-或-(CO)-CH 2-(CH 2OCH 2) 4-CH 2(CO)-，L 3为-(CH 2) 3-，L 4为-(CH 2) 0-，R 2为DOTA，R 3和R 4同为H或者同为F原子。
本发明进一步优选的方案中，所述的化合物tEB-FAPI结构是下式(II-1)至式(II-16)所示的任意一种：
Figure PCTCN2021105637-appb-000009
Figure PCTCN2021105637-appb-000010
Figure PCTCN2021105637-appb-000011
Figure PCTCN2021105637-appb-000012
或者
Figure PCTCN2021105637-appb-000013
在此基础上，本发明进一步提供制备式(II-1)所示化合物tEB-FAPI的方法，包括以下步骤：
①将6-羟基-4-喹啉羧酸与甘氨酸叔丁酯发生酰胺缩合反应；然后依次与1-溴-3氯丙烷和1-叔丁氧羰基哌嗪反应；接着在TFA作用下脱除Boc和叔丁基保护基；再在氨基上引入Boc保护；接着与(S)-吡咯烷-2-甲腈盐酸盐发生酰胺缩合反应；利用对甲基苯磺酸脱除Boc保护；接着与5,8,11,14-四氧杂-2-氮杂十七碳二酸-1-叔丁酯发生缩合反应；再次利用对甲基苯磺酸作用下脱除Boc保护，得到中间体化合物A；
②将4,4'-二氨基-3,3'-二甲基联苯单边引入Boc保护，接着与1-氨基-8-萘酚-2,4-二磺酸单钠盐反应制备截短型伊文思蓝衍生物；脱去Boc保护，接着与N-叔丁氧羰基-L-谷氨酸-1-叔丁酯发生酰胺缩合反应；接着在TFA作用下脱除Boc和叔丁基保护基；然后与二碳酸二叔丁酯反应，在氨基上引入Boc保护，得到中间体化合物B；
③中间体化合物A与中间体化合物B发生酰胺缩合反应；接着利用对甲基苯磺酸脱除Boc保护；最 后与DOTA-NHS反应，得到式(II-1)所示的化合物。
本发明优选的制备式(II-1)所示化合物tEB-FAPI的方法，具体包括以下步骤：
将6-羟基-4-喹啉羧酸(化合物1)和甘氨酸叔丁酯溶解在N,N-二甲基甲酰胺中，加入HATU，得到化合物2；将化合物2溶解在N,N-二甲基甲酰胺中，加入1-溴-3氯丙烷和碳酸钾，加热反应体系到60℃维持一定时间，得到化合物3；将化合物3溶解在N,N-二甲基甲酰胺中，加入1-叔丁氧羰基哌嗪和碘化钾，反应得到化合物4；将化合物4溶解在三氟乙酸溶液中脱除保护基团，得到化合物5；化合物5溶解在N,N-二甲基甲酰胺中，加入二碳酸二叔丁酯和缚酸剂，得到化合物6；化合物6与(S)-吡咯烷-2-甲腈盐酸盐在HATU和DIPEA作用下，发生缩合反应得到化合物7；化合物7在对甲基苯磺酸作用下脱除保护，得到化合物8；化合物8与5,8,11,14-四氧杂-2-氮杂十七碳二酸-1-叔丁酯在HATU和DIPEA作用下，发生缩合反应得到化合物9；将化合物9在对甲基苯磺酸作用下脱除保护，得到化合物10(即所述的中间体化合物A)；
将4,4'-二氨基-3,3'-二甲基联苯(化合物11)与二碳酸二叔丁酯反应，得到化合物12；化合物12与1-氨基-8-萘酚-2,4-二磺酸单钠盐和亚硝酸钠反应，制得截短型伊文思蓝衍生物(化合物13)；化合物13脱除Boc保护，得到化合物14；化合物14与N-叔丁氧羰基-L-谷氨酸-1-叔丁酯在HATU和DIPEA作用下，发生缩合反应得到化合物15；将化合物15溶解在三氟乙酸溶液中脱除保护基团，得到化合物16；化合物16溶解在N,N-二甲基甲酰胺中，加入二碳酸二叔丁酯和缚酸剂，得到化合物17(即所述的中间体化合物B)；
化合物17和化合物10在HATU和DIPEA作用下，发生缩合反应得到化合物18；化合物18在对甲基苯磺酸作用下脱除保护，得到化合物19；化合物19与DOTA-NHS反应，得到最终的式(II-1)所示的化合物20；
上述具体步骤的合成路线如下：
Figure PCTCN2021105637-appb-000014
Figure PCTCN2021105637-appb-000015
本发明方案中的其它tEB-FAPI化合物的制备方法与化合物20的制备方法类似，基本上可以基于现有常规手段参考化合物20的合成路线进行制备。
另一方面，本发明进一步提供一种放射性标记的tEB-FAPI配合物，它是以本发明所述的式(I)化合物为配体，标记放射性核素得到的配合物。所述的放射性标记配合物可以作为新型的肿瘤放射性诊疗探针，即可以作为放射性核素诊断探针或放射性核素治疗探针。所述的核素可以选择 177Lu、 90Y、 18F、 64Cu、 68Ga、 62Cu、 67Cu、 86Y、 89Zr、 99mTc、 89Sr， 153Sm、 149Tb、 161Tb、 186Re、 188Re、 212Pb、 213Bi、 223Ra、 225Ac、 226Th、 227Th、 131I、 211At或 111In中的任意一种；优选 68Ga、 177Lu或 90Y。
本发明优选的所述配合物，其结构如下式(IV)所示：
Figure PCTCN2021105637-appb-000016
其中，
L 1为赖氨酸或谷氨酸结构，或含有赖氨酸或谷氨酸结构的衍生化合物结构；
L 2是-(CH 2) n-，其中n是0至30的整数，其中每个CH 2可以单独地用或不用-O-、-NH-、-(CO)-、-NH(CO)-或-(CO)-NH-替换，替换的条件是没有两个相邻的CH 2基团被替换；
L 3是-(CH 2) m-，其中m是0至30的整数，其中每个CH 2可以单独地用或不用-O-或-(CO)-替换，替换 的条件是没有两个相邻的CH 2基团被替换；
X选自N、C、O、S或者以下结构：
Figure PCTCN2021105637-appb-000017
R 3和R 4相同或不同，均独立的选自H或F；
M为放射性核素，选自 68Ga、 177Lu或 90Y中的任意一种。
本发明优选的配合物方案中，所述式(IV)中的L 2是-(CH 2) n-；n是0-16的整数，更优选是0-12的整数，进一步优选0、3或10；其中每个-CH 2-可以单独地用或不用-O-、-NH-或-(CO)-替换，替换的条件是没有两个相邻的-CH 2-基团被替换。更优选的L 2是-(CH 2) 0、-NH-CH 2-(CO)-、-NH-CH 2-(CH 2OCH 2) 2-CH 2-(CO)-、-NH-CH 2-(CH 2OCH 2) 4-CH 2(CO)-、-(CO)-CH 2-(CO)-、-(CO)-(CH 2) 2-(CO)-、-(CO)-CH 2-(CH 2OCH 2) 2-CH 2(CO)-或-(CO)-CH 2-(CH 2OCH 2) 4-CH 2(CO)-。
本发明优选的配合物方案中，所述式(IV)中的L 3是-(CH 2) m-；m是0-20的整数，更优选是1-6的整数，进一步优选2或3；其中每个-CH 2-可以单独地用或不用-O-替换，替换的条件是没有两个相邻的-CH 2-基团被替换。更优选的L 3是-(CH 2) 3-。
本发明所述的放射性标记配合物可以通过含放射性核素的化合物与本发明所述的式(I)化合物按照现有的多种标记方法制备得到；本发明优选的标记方法为下述的湿法或冻干法：
湿法标记方案，包括：将适量本发明所述的式(I)化合物溶于缓冲溶液或去离子水中；在所得溶液中加入放射性核素溶液，密闭反应5-40min，即生成放射性核素标记的配合物；
或者，冻干法标记方案，包括：将适量本发明所述的式(I)化合物溶于缓冲溶液或去离子水中；将所得溶液经无菌过滤后，分装于容器中，经冷冻干燥后加塞密封，得到冻干药盒；向所述冻干药盒中加入适量乙酸溶液或缓冲液溶解，再加入相应的放射性核素溶液，密闭反应5-40min，即生成放射性核素标记的配合物。其中，所述的分装用容器优选为冻存管或管制抗生素瓶。还可以根据药盒冻干粉成型情况选择在药盒中增加赋形剂，比如甘露醇、抗坏血酸等，并通过调节本发明所述的式(I)化合物及赋形剂的用量，使药盒成型达到最佳。
所述的湿法标记方案和冻干标记方案得到的产物均可经常规处理(如经色谱分离纯化、旋蒸除去溶剂、以PBS或水或生理盐水溶解剩余物、无菌过滤等)进一步制成注射液。
本发明一种优选的具体实施方式中，以式(II-1)所示的化合物20为配体，放射性标记化合物20的优选的一种制备方法是湿法标记法，包括以下步骤：将化合物20溶于缓冲溶液或去离子水中；在其中加入新鲜的放射性溶液，密闭37-90℃反应5-40min，冷却；加水稀释反应液后经Sep-Pak C18色谱柱分离纯化，以缓冲液或水冲洗色谱柱以除去未反应的放射性离子，以盐酸乙醇溶液或乙醇溶液淋洗，再经生理盐水或PBS稀释后无菌过滤，即得到结构如式(IV-1)所述的放射性标记的配合物的注射液；其中放射性核素M为 68Ga、 177Lu或 90Y等。
Figure PCTCN2021105637-appb-000018
本发明放射性标记化合物20的另一种优选的制备方法是冻干法标记法，包括：将化合物20和其他必要试剂溶于缓冲液中，所得溶液经无菌过滤后分装于冻存管中，经冷冻干燥后密封得到冻干药盒；向冻干药盒中加入适量缓冲溶液溶解，再加入新鲜制的放射性溶液，密闭37-120℃反应5-40min，冷却；加水稀释反应液后经Sep-Pak C18色谱柱分离纯化，以缓冲液或水冲洗色谱柱以除去未反应的放射性离子，以盐酸乙醇溶液或乙醇溶液淋洗，再经生理盐水或PBS稀释后无菌过滤得到即得到结构如式(IV-1)所示的放射性标记的配合物的注射液；其中放射性核素M为 68Ga、 177Lu或 90Y等。
上述合成步骤中的所使用的其它化学物质为市售商品。
所述缓冲溶液为稳定反应液pH值的物质，可以为醋酸盐、乳酸盐、酒石酸盐、苹果酸盐、马来酸盐、琥珀酸盐、抗坏血酸盐、碳酸盐和磷酸盐，以及它们的混合物等。
再一个方面，本发明还提供式(I)所示tEB-FAPI化合物或其药学上可接受的盐在制备FAP蛋白高表达肿瘤的核素治疗或显像药物中的应用。
本发明还提供式(IV)所示放射性标记的tEB-FAPI配合物在FAP蛋白高表达肿瘤的核素治疗和显像中的应用。
本发明优选的所述应用中，所述的配合物被制备成注射剂，通过静脉注射给药，用于FAP蛋白高表达肿瘤患者。
本发明所述的应用中，所述的FAP蛋白高表达肿瘤包括但不限于乳腺癌、卵巢癌、肺癌、结直肠癌、胃癌或胰腺癌。
本发明提供一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂tEB-FAPI及其放射性核素标记的配合物，并提供了该类化合物的制备方法和标记方法。生物试验结果表明其具有显著延长的血液循环半衰期、增强的肿瘤摄取富集和保留时间。这种新颖性能是目前其它FAPI显像剂所不具备的，其适合用作FAP蛋白高表达肿瘤的核素治疗和显像。
附图说明
图1为本发明实施例1中的化合物2的质谱图。
图2为本发明实施例1中的化合物2的核磁氢谱。
图3为本发明实施例1中的化合物2的核磁碳谱。
图4为本发明实施例1中的化合物3的质谱图。
图5为本发明实施例1中的化合物3的核磁氢谱。
图6为本发明实施例1中的化合物4的质谱图。
图7为本发明实施例1中的化合物4的核磁氢谱。
图8为本发明实施例1中的化合物4的核磁碳谱。
图9为本发明实施例1中的化合物7的质谱图。
图10为本发明实施例1中的化合物7的核磁氢谱。
图11为本发明实施例1中的化合物7的核磁碳谱。
图12为本发明实施例1中的化合物10的质谱图。
图13为本发明实施例1中的化合物20的质谱图。
图14为本发明实施例10中的化合物的质谱图。
图15为本发明实施例11中的化合物的质谱图。
图16为本发明实施例1中的化合物10的HPLC色谱图。
图17为本发明实施例1中的化合物17的HPLC色谱图。
图18为本发明实施例1中的化合物17与化合物10反应体系的HPLC色谱图。
图19为本发明实施例1中的化合物19的HPLC色谱图。
图20为本发明实施例1中的化合物19与DOTA-NHS反应体系的HPLC色谱图。
图21A和图21B体现了本发明中68Ga标记的tEB-FAPI配合物与68Ga标记的FAPI-02在正常小鼠体内的MicroPET显像。
图22体现了本发明实施例40制备的177Lu-tEB-FAPI在正常小鼠体内不同时间点的SPECT显像。
图23体现了本发明实施例40制备的177Lu-tEB-FAPI在人源胰腺癌异种移植模型小鼠不同时间点的SPECT显像。
具体实施方式
以下通过具体实施方式结合附图对本发明的技术方案进行进一步的说明和描述。
实施例1：tEB-FAPI连接物(化合物20)的制备
化合物2的合成：
在100mL烧瓶中分别投入化合物1(6-羟基-4-喹啉羧酸，1.89g，10.0mmol)、甘氨酸叔丁酯(1.89g，10.0mmol)，HATU(3.8g，10.0mmol)和N,N-二异丙基乙胺(2.6g，20.0mmol)依次投入至30mL N,N-二甲基甲酰胺。反应混合物搅拌过夜，减压蒸馏除去溶剂，得到粗产物。经硅胶柱(二氯甲烷/甲醇＝30:1)纯化得白色固体化合物2，产率87％，图1为化合物2的质谱图，图2显示了化合物2的核磁氢谱，图3显示了化合物2的核磁碳谱。
化合物3的合成：
在100mL烧瓶中分别将化合物2(1.51g，5.0mmol))、1-溴-3-氯丙烷(1.55g，10.0mmol)，碳酸钾(1.38g，10.0mmol)依次投入至50mL N,N-二甲基甲酰胺中。将体系升温到60度，保持体系60度搅拌过夜，减压蒸馏除去溶剂，得到粗产物。经硅胶柱(二氯甲烷/甲醇＝50：1)纯化得白色固体化合物3，产率63％，图4为化合物3的质谱图，图5显示了化合物3的核磁氢谱。
化合物4的合成：
在100mL烧瓶中分别将化合物3(0.76g，2.0mmol)、1-叔丁氧羰基哌嗪(0.55g，3.0mmol)，和碘化钾(0.49g，3.0mmol)依次投入至30mL乙腈中。将体系升温到60摄氏度，保持体系60摄氏度搅拌过夜，减压蒸馏除去溶剂，得到粗产物。经硅胶柱(二氯甲烷/甲醇＝30:1)纯化得白色固体化合物4，产率58％。MS(ESI)m/z calculatedfor[C 28H 40N 4O 6]:528.29；found:529.10[M+H] +.图6为化合物4的质谱图，图7显示了化合物4的核磁氢谱，图8显示了化合物4的核磁碳谱。
化合物5的合成：
在冰浴条件下，将化合物4(0.52g，1.0mmol)溶解在10mL二氯甲烷和三氟乙酸(体积比9:1)混合溶液中，将体系升温到室温反应2h，反应结束后减压蒸馏除去溶剂，用10mLN,N-二甲基甲酰胺溶解，备用。
化合物6的合成：
向化合物5的N,N-二甲基甲酰胺中分别加入二碳酸二叔丁酯(0.22g，1.0mmol)和N,N-二异丙基乙胺(0.39g，3.0mmol)，室温搅拌过夜，减压蒸馏除去溶剂，得到粗产物。经硅胶柱(二氯甲烷/甲醇＝10:1)纯化得白色固体化合物6，产率72％。
化合物7的合成：
在100mL烧瓶中分别投入化合物6(0.47g，1.0mmol)、(S)-吡咯烷-2-甲腈盐酸盐(0.13g，10.0mmol)，HATU(0.38g，1.0mmol)和N,N-二异丙基乙胺(0.26g，2.0mmol)依次投入至10mL N,N-二甲基甲酰胺。反应混合物室温搅拌至反应结束，减压蒸馏除去溶剂，得到粗产物。经硅胶柱(二氯甲烷/甲醇＝50:1)纯化得白色固体化合物7，产率85％。图9为化合物7的质谱图，图10显示了化合物7的核磁氢谱，图11显示了化合物7的核磁碳谱。
化合物8的合成：
在100mL烧瓶中分别投入化合物7(0.55g，1.0mmol)和对甲苯磺酸一水合物(0.27g，1.5mmol)依次投入至10mL乙腈中。反应体系升温至60摄氏度搅拌至反应结束，减压蒸馏除去溶剂，得到粗产物。
化合物9的合成：
在上述化合物8的反应烧瓶中分别投入5,8,11,14-四氧杂-2-氮杂十七碳二酸-1-叔丁酯(0.19g，1.0mmol)，HATU(0.38g,1.0mmol)和N,N-二异丙基乙胺(0.26g，2.0mmol)以及10mL N,N-二甲基甲酰胺。反应混合物搅拌过夜，减压蒸馏除去溶剂，得到粗产物。经硅胶柱(二氯甲烷/甲醇＝50:1)纯化得白色固体化合物9，产率64％。
化合物10的合成：
在100mL烧瓶中分别投入化合物9(0.61g，1.0mmol)和对甲苯磺酸一水合物(0.27g，1.5mmol)依次投入至10mL乙腈中。反应体系升温至60摄氏度搅拌至反应结束，减压蒸馏除去溶剂，得到粗产物。经硅胶柱(二氯甲烷/甲醇＝10:1)纯化得白色固体化合物10，产率59％。MS(ESI)m/z calculatedfor[C 35H 51N 7O 8]:697.38；found:698.43[M+H] +.图12为化合物10的质谱图。
上述步骤合成路线如下：
Figure PCTCN2021105637-appb-000019
化合物12的合成：
在100mL烧瓶中分别投入4,4'-二氨基-3,3'-二甲基联苯(化合物11)(2.12g，10.0mmol)、二碳酸二 叔丁酯(2.2g，10.0mmol)和N,N-二异丙基乙胺(1.3g，10.0mmol)以及20mL二氯甲烷，室温搅拌过夜，通过HPLC监测反应完成(r.t.为10.13分钟)减压蒸馏除去溶剂，得到粗产物，经硅胶柱(石油醚/乙酸乙酯＝5:1)纯化得白色固体化合物12，产率59％。
化合物13的合成：
在50mL烧瓶中分别投入化合物12(0.31g，1.0mmol)和4mL的乙腈，冰浴，将2M的盐酸1.5mL的滴加进反应瓶中，反应15min，加入亚硝酸钠(0.068g，1.0mmol)溶解在2mL水中，再次滴加进反应瓶中，反应半个小时，作为A液待用。另外准备一个50mL的反应烧瓶，加入1-氨基-8-萘酚-2,4-二磺酸单钠盐(0.33g，1.0mmol)、碳酸钠(0.105g，1.0mmol)以及5mL水，冰浴，将A液缓慢滴加入B液，冰浴搅拌反应2h。经反相柱化，冷冻干燥得到纯的化合物13，产率47％。
化合物14的合成：
在冰浴条件下，将化合物13(0.52g，1.0mmol)溶解在三氟乙酸中，将体系升温到室温反应2h，反应结束后减压蒸馏除去溶剂，得到粗产物。将粗产物经反相柱化，冷冻干燥得到纯的化合物14，产率73％。
化合物15的合成：
在100mL烧瓶中分别投入化合物14(0.54g，1.0mmol)、N-叔丁氧羰基-L-谷氨酸-1-叔丁酯(0.30g，1.0mmol)，HATU(0.38g,1.0mmol)和N,N-二异丙基乙胺(0.26g，2.0mmol)以及10mL N,N-二甲基甲酰胺。反应混合物搅拌至反应结束，减压蒸馏除去溶剂，得到粗产物。将粗产物经反相柱化，冷冻干燥得到纯的化合物15，产率52％。
化合物16的合成：
使用硫代苯甲醚：1,2-乙二硫醇:苯甲醚:TFA(5:3:2:90)在室温下下进行脱处叔丁酯和Boc保护。反应结束后，通过氩气流除去TFA，接着用10mLN,N-二甲基甲酰胺溶解，备用。
化合物17的合成：
向化合物16的N,N-二甲基甲酰胺中分别加入二碳酸二叔丁酯(0.22g，1.0mmol)和N,N-二异丙基乙胺(0.39g，3.0mmol)，室温搅拌过夜，通过HPLC监测反应完成(r.t.为10.84分钟)。减压蒸馏除去溶剂，得到粗产物。将粗产物经反相柱化，冷冻干燥得到纯的化合物17，两步产率43％。
化合物18的合成：
在50mL烧瓶中分别投入化合物17(0.77g，1.0mmol)、化合物10(0.51g，1.0mmol)，HATU(0.38g，1.0mmol)和N,N-二异丙基乙胺(0.26g，2.0mmol)以及10mL N,N-二甲基甲酰胺。反应混合物搅拌反应，通过HPLC监测反应完成(r.t.为12.16分钟)。减压蒸馏除去溶剂，得到粗产物。将粗产物经反相柱化，冷冻干燥得到纯的化合物18，产率55％。
化合物19的合成：
在25mL烧瓶中分别投入化合物15(0.13g，0.1mmol)和对甲苯磺酸一水合物(0.05g，0.3mmol)依次投入至5mL乙腈中。反应体系升温至60摄氏度搅拌反应，通过HPLC监测脱保护进程至反应结束(r.t.为10.47分钟)，减压蒸馏除去溶剂，得到粗产物。将粗产物经反相柱化，冷冻干燥得到纯的化合物19，产率61％。
化合物20的合成：
在25mL烧瓶中分别投入化合物19(0.12g，0.1mmol)、DOTA-NHS(0.05g，0.1mmol)以及N,N-二异丙基乙胺(0.04g，0.3mmol)依次投入至5mL N,N-二甲基甲酰胺。反应体系室温搅拌反应，通过HPLC监测脱至反应结束(r.t.为11.35分钟)，减压蒸馏除去溶剂，得到粗产物。将粗产物经反相柱化，冷冻干 燥得到纯的化合物20，产率53％。MS(ESI)m/z calculatedfor[C 80H 104N 16O 24S 2]:1736.69；found:1737.743[M+H] +.图13为化合物20的质谱图。
上述步骤合成路线如下：
Figure PCTCN2021105637-appb-000020
实施例2-16
实施例2-16的化合物结构分别如式(II-2)至式(II-16)所示，它们的制备方法均可参考实施例1，将其中与化合物14反应的谷氨酸结构替换为赖氨酸结构，或将与化合物8反应的5,8,11,14-四氧杂-2-氮杂十七碳二酸-1-叔丁酯替换成5,8,11-三氧杂-2-氮杂十三烷二酸-1-叔丁酯、9-氨基-4,7-二氧杂壬酸叔丁酯、甘氨酸叔丁酯或其他合适的化合物，或将与化合物6反应的(S)-吡咯烷-2-甲腈盐酸盐替换成3,3-二氟吡咯烷盐酸盐，或同时替换，得到如下相应的结构：
Figure PCTCN2021105637-appb-000021
Figure PCTCN2021105637-appb-000022
Figure PCTCN2021105637-appb-000023
或者
Figure PCTCN2021105637-appb-000024
其中，实施例10中的化合物(II-10)的质谱图见图14；实施例11(II-11)的化合物的质谱图见图15。
实施例17-38：
参考实施例1-16的制备方法，制备以下式(I)表达的tEB-FAPI化合物：
Figure PCTCN2021105637-appb-000025
Figure PCTCN2021105637-appb-000026
Figure PCTCN2021105637-appb-000027
实施例39.放射性Ga-68标记tEB-FAPI配合物的制备：
湿法：将约18.5～1850兆贝可(MBq) 68GaCl 3盐酸溶液(淋洗自锗镓发生器)加入到含0.5mL实施例1制备的化合物20的醋酸-醋酸盐溶液(1.0g/L)的离心管中，置于37℃下反应20min。取一C18分离小柱，先用10mL无水乙醇缓慢淋洗，再用10mL水淋洗。用10mL水将标记液稀释后，上样到分离柱上，先用10mL水除去未标记的 68Ga离子，再用0.3mL 10mM的HCl的乙醇溶液淋洗得到 68Ga标记的tEB-FAPI配合物。该淋洗液经生理盐水稀释，并经无菌过滤后即得 68Ga标记的tEB-FAPI配合物的注射液。
冻干法：将约18.5～1850兆贝可(MBq) 68GaCl 3盐酸溶液(淋洗自锗镓发生器)加入到含有化合物20的冻干药盒中，混匀后37℃下反应20min。取一C18分离小柱，先用10mL无水乙醇缓慢淋洗，再用10mL水淋洗。用10mL水将标记液稀释后，上样到分离柱上，先用10mL水除去未标记的 68Ga离子，再用0.3mL 10mM的HCl的乙醇溶液淋洗得到配合物淋洗液。该淋洗液经生理盐水稀释，并经无菌过滤后即得 68Ga标记的tEB-FAPI配合物的注射液。
实施例40.一种Lu-177标记的tEB-FAPI配合物的制备：
湿法：将约18.5～1850MBq 177LuCl 3醋酸钠溶液分别加入到含0.5mL实施例1化合物20、实施例2(式II-2化合物)和实施例3(式II-3化合物)的化合物的醋酸-醋酸盐溶液(1.0g/L)的三个离心管中，置于90℃下反应20min。取一C18分离小柱，先用10mL无水乙醇缓慢淋洗，再用10mL水淋洗。用10mL水将标记液稀释后，上样到分离柱上，先用10mL水除去未标记的 177Lu离子，再用0.3mL 10mM的HCl的乙醇溶液淋洗得到三个 177Lu标记的tEB-FAPI配合物。该淋洗液经生理盐水稀释，并经无菌过滤后即得三个 177Lu标记的tEB-FAPI配合物的注射液。
冻干法：将约18.5～1850MBq 177LuCl 3醋酸钠溶液分别加入到含有实施例1化合物20、实施例2(式II-2化合物)和实施例3(式II-3化合物)的三个冻干药盒中，混匀后90℃下反应20min。取一C18分离小柱，先用10mL无水乙醇缓慢淋洗，再用10mL水淋洗。用10mL水将标记液稀释后，上样到分离柱上，先用10mL水除去未标记的 177Lu离子，再用0.3mL 10mM的HCl的乙醇溶液淋洗得到三个 77Lu标记的tEB-FAPI配合物淋洗液。该淋洗液经生理盐水稀释，并经无菌过滤后即得三个 177Lu标记的tEB-FAPI配合物的注射液。
实验例.分析及应用效果
1、HPLC分析鉴定
HPLC体系如下：SHIMADZULC-20A；C18色谱柱(YMC，3μm，4.6×150mm)用于分析。检测波长254nm，流速为1mL/min，淋洗梯度：0～3分钟：10％乙腈0和90％水(50mM醋酸铵)保持不变；3-16分钟：增加到90％乙腈和10％水(50mM醋酸铵)；16-18min：保持90％乙腈和10％水(50mM醋酸铵)；18-20min：降低到10％乙腈和90％水(50mM醋酸铵)；20-22min：保持10％乙腈和90％水(50mM醋酸铵)。
按上述体系对实施例1中的化合物10、化合物17、化合物10与化合物17反应体系、化合物19、以及化合物19与DOTA-NHS反应体系进行鉴定分析，得到的结果如图16-图20所示。
以下以实施例39、实施例40制备的两种放射性标记探针为实验用药剂，其性能测定描述如下：
2、 68Ga标记的tEB-FAPI配合物在正常小鼠体内的MicroPET显像
按实施例39的方法制备好纯度大于95％的 68Ga-tEB-FAPI，在正常FVB小鼠中，经尾静脉注射3.7MBq的 68Ga-tEB-FAPI或者 68Ga-FAPI-02(作为对照)，然后在异氟烷麻醉下，分别于给药后0～120min进行MicroPET显像，结果见图21A和图21B。结果显示，实施例39的配合物 68Ga-tEB-FAPI在小鼠心血池内有较高摄取(图21A)，而 68Ga-FAPI-02在测试时间内几乎被完全清除(图21B)，表明截短型伊文思蓝的引入能够显著延长循环半衰期。
3、 177Lu标记的tEB-FAPI配合物在人源胰腺癌异种移植模型小鼠肿瘤摄取实验。
按实施例40的方法制备好纯度大于95％的 177Lu-tEB-FAPI(基于实施例1的化合物20)，分别在正常小鼠和人源胰腺癌异种移植模型小鼠中，经尾静脉注射1.3MBq的 177Lu-tEB-FAPI。在注射后不同时间点进行SPECT显像，正常小鼠的SPECT显像结果见图22，人源胰腺癌异种移植模型小鼠的SPECT显像结果见图23。结果显示， 177Lu-tEB-FAPI在正常小鼠体内具有良好的药代动力学，在人源胰腺癌异种移植模型小鼠中能够持续被肿瘤组织摄取并维持超过48h，表明tEB-FAPI具有显著增强的肿瘤摄取和保留时间，可以用作肿瘤治疗剂及显像剂。
综上所述，本发明提供的截短型伊文思蓝的修饰的成纤维活化蛋白抑制剂能够显著延长其循环半衰期，并且能够增强肿瘤摄取富集和保留时间，这种新颖性能是目前其它FAPI显像剂所不具备的。经进一步临床前动物水平及临床研究证实，其有望成为FAP蛋白高表达肿瘤的核素治疗和显像。
虽然，上文中已经用一般性说明、具体实施方式及试验，对本发明作了详尽的描述，但在本发明基础上，可以对之作一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。

Claims (20)

  1. 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂化合物或其药学上可用的盐，其特征在于：其分子结构是由连接基团L 1、L 2、L 3、L 4和X将截短型伊文思蓝、成纤维细胞活化蛋白抑制剂和核素螯合基团连接在一起构成，其结构如下式(I)所示
    Figure PCTCN2021105637-appb-100001
    其中：
    L 1为赖氨酸、谷氨酸或含有赖氨酸或谷氨酸结构的衍生化合物；
    L 2是-(CH 2) n-，其中n是0至30的整数，其中每个-CH 2-单独地用或不用-O-、-NH-、-(CO)-、-NH(CO)-或-(CO)-NH-替换，替换的条件是没有两个相邻的-CH 2-基团被替换；
    L 3是-(CH 2) m-，其中m是0至30的整数，其中每个-CH 2-单独地用或不用-O-或-(CO)-替换，替换的条件是没有两个相邻的-CH 2-基团被替换；
    L 4是-(CH 2) p-，其中p是0至30的整数，其中每个-CH 2-单独地用或不用-O-、-NH-、-(CO)-、-NH(CO)-或-(CO)-NH-替换，替换的条件是没有两个相邻的-CH 2-基团被替换；
    X选自N、C、O、S或者以下结构中的任意一种：
    Figure PCTCN2021105637-appb-100002
    R 1为以下成纤维细胞活化蛋白抑制剂结构：
    Figure PCTCN2021105637-appb-100003
    R 2是核素螯合基团，选自以下任意一种结构：
    Figure PCTCN2021105637-appb-100004
    R 3-R 4相同或不同，均独立的选自H或F。
  2. 权利要求1所述的化合物，其特征在于：所述式(I)中的L 2是-(CH 2) n-；n是0-16的整数，更优 选是0-12的整数，进一步优选0、3或10；其中每个-CH 2-单独地用或不用-O-、-NH-或-(CO)-替换，替换的条件是没有两个相邻的-CH 2-基团被替换。
  3. 权利要求1所述的化合物，其特征在于：所述式(I)中的L 3是-(CH 2) m-；m是0-20的整数，更优选是1-6的整数，进一步优选2或3；其中每个-CH 2-可以单独地用或不用-O-替换，替换的条件是没有两个相邻的-CH 2-基团被替换。
  4. 权利要求1所述的化合物，其特征在于：所述式(I)中的L 4是-(CH 2) p-；p是0-20的整数，更优选是0-12的整数，进一步优选3、4、9或12，最优选3；其中每个-CH 2-可以单独地用或不用-O-、-NH-、-(CO)-、-NH(CO)-或-(CO)-NH-替换，替换的条件是没有两个相邻的-CH 2-基团被替换。
  5. 权利要求1所述的化合物，其特征在于：所述式(I)中的X为
    Figure PCTCN2021105637-appb-100005
    L 3为-(CH 2) 3-，L 4为-(CH 2) 0-，R 2为
    Figure PCTCN2021105637-appb-100006
    即所述化合物结构如下式(II)所示：
    Figure PCTCN2021105637-appb-100007
    其中R 3和R 4同为H或者同为F原子，L 1为谷氨酸或赖氨酸结构，L 2为-(CH 2) 0-、-NH-CH 2-(CO)-、-NH-CH 2-(CH 2OCH 2) 2-CH 2-(CO)-、-NH-CH 2-(CH 2OCH 2) 4-CH 2(CO)-、-(CO)-CH 2-(CO)-、-(CO)-(CH 2) 2-(CO)-、-(CO)-CH 2-(CH 2OCH 2) 2-CH 2(CO)-或-(CO)-CH 2-(CH 2OCH 2) 4-CH 2(CO)-。
  6. 权利要求1所述的化合物，其特征在于：所述式(I)中的X为
    Figure PCTCN2021105637-appb-100008
    L 1为谷氨酸结构，L 2为-(CH 2) 0-、-NH-CH 2-(CO)-、-NH-CH 2-(CH 2OCH 2) 2-CH 2-(CO)-或-NH-CH 2-(CH 2OCH 2) 4-CH 2(CO)-，L 3为-(CH 2) 3-，L 4为-(CH 2) 0-，R 2为DOTA，R 3和R 4同为H或者同为F原子。
  7. 权利要求1所述的化合物，其特征在于：所述式(I)中的X为
    Figure PCTCN2021105637-appb-100009
    L 1为赖氨酸结构，L 2为-(CO)-CH 2-、-(CO)-、-(CO)-(CH 2) 2-(CO)-、-(CO)-CH 2-(CH 2OCH 2) 2-CH 2(CO)-或-(CO)-CH 2-(CH 2OCH 2) 4-CH 2(CO)-，L 3为-(CH 2) 3-，L 4为-(CH 2) 0-，R 2为DOTA，R 3和R 4同为H或者同为F原子。
  8. 权利要求1所述的化合物，其特征在于：所述的化合物结构是以下式(II-1)至式(II-16)所示的任意一种：
    Figure PCTCN2021105637-appb-100010
    Figure PCTCN2021105637-appb-100011
    Figure PCTCN2021105637-appb-100012
    Figure PCTCN2021105637-appb-100013
  9. 制备截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂的方法，其特征在于：包括以下步骤：
    ①将6-羟基-4-喹啉羧酸与甘氨酸叔丁酯发生酰胺缩合反应；然后依次与1-溴-3氯丙烷和1-叔丁氧羰基哌嗪反应；接着在TFA作用下脱除Boc和叔丁基保护基；再在氨基上引入Boc保护；接着与(S)-吡咯烷 -2-甲腈盐酸盐发生酰胺缩合反应；利用对甲基苯磺酸脱除Boc保护；接着与5,8,11,14-四氧杂-2-氮杂十七碳二酸-1-叔丁酯发生缩合反应；再次利用对甲基苯磺酸作用下脱除Boc保护，得到中间体化合物A；
    ②将4,4'-二氨基-3,3'-二甲基联苯单边引入Boc保护，接着与1-氨基-8-萘酚-2,4-二磺酸单钠盐反应制得截短型伊文思蓝衍生物；脱去Boc保护，接着与N-叔丁氧羰基-L-谷氨酸-1-叔丁酯发生酰胺缩合反应；接着在TFA作用下脱除Boc和叔丁基保护基；然后与二碳酸二叔丁酯反应，在氨基上引入Boc保护，得到中间体化合物B；
    ③将①得到的中间体化合物A与②得到的中间体化合物B发生酰胺缩合反应；接着利用对甲基苯磺酸脱除Boc保护；最后与DOTA-NHS反应，得到结构如下式(II-1)所示的截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂化合物
    Figure PCTCN2021105637-appb-100014
  10. 一种放射性标记的截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂配合物，它是以权利要求1所述的式(I)化合物为配体标记放射性核素得到的配合物；所述的放射性核素优选 177Lu、 90Y、 18F、 64Cu、 68Ga、 62Cu、 67Cu、 86Y、 89Zr、 99mTc、 89Sr， 153Sm、 149Tb、 161Tb、 186Re、 188Re、 212Pb、 213Bi、 223Ra、 225Ac、 226Th、 227Th、 131I、 211At或 111In中的任意一种；进一步优选的放射性核为 68Ga、 177Lu或 90Y。
  11. 一种放射性标记的截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂配合物，其结构如下式(IV)所示：
    Figure PCTCN2021105637-appb-100015
    其中，
    L 1为赖氨酸或谷氨酸结构，或含有赖氨酸或谷氨酸结构的衍生化合物结构；
    L 2是-(CH 2) n-，其中n是0至30的整数，其中每个CH 2单独地用或不用-O-、-NH-、-(CO)-、-NH(CO)-或-(CO)-NH-替换，替换的条件是没有两个相邻的CH 2基团被替换；
    L 3是-(CH 2) m-，其中m是0至30的整数，其中每个CH 2单独地用或不用-O-或-(CO)-替换，替换的条件是没有两个相邻的CH 2基团被替换；
    X选自N、C、O、S或者以下结构：
    Figure PCTCN2021105637-appb-100016
    R 3和R 4相同或不同，均独立的选自H或F；
    M为放射性核素，选自 68Ga、 177Lu或 90Y中的任意一种。
  12. 权利要求11所述的配合物，其特征在于：所述式(IV)中的L 2是-(CH 2) n-；n是0-16的整数，更优选是0-12的整数，进一步优选0、3或10；其中每个-CH 2-单独地用或不用-O-、-NH-或-(CO)-替换，替换的条件是没有两个相邻的-CH 2-基团被替换。
  13. 权利要求11所述的配合物，其特征在于：所述式(IV)中的L 2是-(CH 2) 0、-NH-CH 2-(CO)-、-NH-CH 2-(CH 2OCH 2) 2-CH 2-(CO)-、-NH-CH 2-(CH 2OCH 2) 4-CH 2(CO)-、-(CO)-CH 2-(CO)-、-(CO)-(CH 2) 2-(CO)-、-(CO)-CH 2-(CH 2OCH 2) 2-CH 2(CO)-或-(CO)-CH 2-(CH 2OCH 2) 4-CH 2(CO)-。
  14. 权利要求11所述的配合物，其特征在于：所述式(IV)中的L 3是-(CH 2) m-；m是0-20的整数，更优选是1-6的整数，进一步优选2或3；其中每个-CH 2-单独地用或不用-O-替换，替换的条件是没有两个相邻的-CH 2-基团被替换。
  15. 权利要求11所述的配合物，其特征在于：所述式(IV)中的L 3是-(CH 2) 3-。
  16. 制备放射性标记的截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂配合物的方法，包括以下步骤：将权利要求1所述的式(I)化合物溶于缓冲溶液或去离子水中；在所得溶液中加入放射性核素溶液，密闭反应5-40min，即生成放射性核素标记的配合物。
  17. 制备放射性标记的截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂配合物的方法，包括以下步骤：将权利要求1所述的式(I)化合物溶于缓冲溶液或去离子水中；将所得溶液经无菌过滤后，分装于容器中，经冷冻干燥后加塞密封，得到冻干药盒；向所述冻干药盒中加入适量乙酸溶液或缓冲液溶解，再加入相应的放射性核素溶液，密闭反应5-40min，即生成放射性核素标记的配合物。
  18. 权利要求1-8任意一项所述化合物或其药学上可接受的盐在制备FAP蛋白高表达肿瘤的核素治疗或显像药物中的应用。
  19. 权利要求10-15任意一项所述的配合物在FAP蛋白高表达肿瘤的核素治疗或显像中的应用。
  20. 权利要求18或19任意一项所述的应用，其特征在于：所述的化合物或配合物被制备成注射剂，通过静脉注射给药，用于FAP蛋白高表达肿瘤患者；所述的FAP蛋白高表达肿瘤包括但不限于乳腺癌、卵巢癌、肺癌、结直肠癌、胃癌或胰腺癌。
PCT/CN2021/105637 2021-02-10 2021-07-11 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用 WO2022170732A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA3210863A CA3210863A1 (en) 2021-02-10 2021-07-11 Truncated evans blue modified fibroblast activation protein inhibitor, preparation method and application thereof
JP2023531665A JP2023545213A (ja) 2021-02-10 2021-07-11 切断型エバンスブルー修飾線維芽細胞活性化タンパク質阻害剤及びその調製方法と応用
CN202180096379.9A CN117120428A (zh) 2021-02-10 2021-07-11 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
AU2021427618A AU2021427618B2 (en) 2021-02-10 2021-07-11 Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof
EP21925385.3A EP4227300A4 (en) 2021-02-10 2021-07-11 ASTRIDGED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, METHOD OF PREPARING THE SAME AND USE THEREOF
US18/257,063 US11975079B2 (en) 2021-02-10 2021-07-11 Truncated Evans Blue modified fibroblast activation protein inhibitor, preparation method and application thereof
KR1020237014883A KR102648429B1 (ko) 2021-02-10 2021-07-11 절단형 에반스 블루 변형의 섬유아세포 활성화 단백질 억제제 및 이의 제조 방법과 응용
ZA2023/08458A ZA202308458B (en) 2021-02-10 2023-08-31 Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110182478.0 2021-02-10
CN202110182478.0A CN114369084B (zh) 2021-02-10 2021-02-10 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN202110753794.9 2021-07-03
CN202110753794.9A CN113582975A (zh) 2021-07-03 2021-07-03 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用

Publications (1)

Publication Number Publication Date
WO2022170732A1 true WO2022170732A1 (zh) 2022-08-18

Family

ID=82837457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/105637 WO2022170732A1 (zh) 2021-02-10 2021-07-11 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用

Country Status (9)

Country Link
US (1) US11975079B2 (zh)
EP (1) EP4227300A4 (zh)
JP (1) JP2023545213A (zh)
KR (1) KR102648429B1 (zh)
CN (1) CN117120428A (zh)
AU (1) AU2021427618B2 (zh)
CA (1) CA3210863A1 (zh)
WO (1) WO2022170732A1 (zh)
ZA (1) ZA202308458B (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
WO2020160222A2 (en) * 2019-01-30 2020-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugates of bivalent evans blue dye derivatives and methods of use
CN111699181A (zh) * 2018-02-06 2020-09-22 海德堡大学 Fap抑制剂
CN113004371A (zh) * 2021-03-01 2021-06-22 上海蓝纳成生物技术有限公司 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809982RA (en) 2016-05-09 2018-12-28 Us Health Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
SG11202002882VA (en) * 2017-10-03 2020-04-29 The United States Of America As Represented By The Secretary Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
US20210008232A1 (en) * 2018-02-22 2021-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
AU2020310538A1 (en) 2019-07-08 2022-01-27 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
CN114790193B (zh) * 2020-12-21 2024-05-10 苏州药明博锐生物科技有限公司 成纤维细胞活化蛋白抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
CN111699181A (zh) * 2018-02-06 2020-09-22 海德堡大学 Fap抑制剂
WO2020160222A2 (en) * 2019-01-30 2020-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugates of bivalent evans blue dye derivatives and methods of use
CN113004371A (zh) * 2021-03-01 2021-06-22 上海蓝纳成生物技术有限公司 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KELLY, J. M. ET AL.: "A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα)", A TRIFUNCTIONAL THERANOSTIC LIGAND TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (FAPΑ), vol. 23, 15 March 2021 (2021-03-15), XP037553830, DOI: 10.1007/s11307-021-01593-1 *
LAU JOSEPH, JACOBSON ORIT, NIU GANG, LIN KUO-SHYAN, BÉNARD FRANÇOIS, CHEN XIAOYUAN: "Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 30, no. 3, 20 March 2019 (2019-03-20), US , pages 487 - 502, XP055959109, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.8b00919 *
ORIT JACOBSON, DALE O. KIESEWETTER, XIAOYUAN CHEN: "Albumin-Binding Evans Blue Derivatives for Diagnostic Imaging and Production of Long-Acting Therapeutics", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 27, no. 10, 19 October 2016 (2016-10-19), US , pages 2239 - 2247, XP055666945, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.6b00487 *
See also references of EP4227300A4 *

Also Published As

Publication number Publication date
EP4227300A1 (en) 2023-08-16
CN117120428A (zh) 2023-11-24
CA3210863A1 (en) 2022-08-18
EP4227300A4 (en) 2024-04-24
US20230390421A1 (en) 2023-12-07
ZA202308458B (en) 2023-10-25
KR20230104145A (ko) 2023-07-07
AU2021427618A1 (en) 2023-06-15
AU2021427618B2 (en) 2023-08-17
US11975079B2 (en) 2024-05-07
KR102648429B1 (ko) 2024-03-18
JP2023545213A (ja) 2023-10-26

Similar Documents

Publication Publication Date Title
WO2022183993A1 (zh) 一种前列腺特异性膜抗原靶向化合物及其制备方法和应用
CN114369084B (zh) 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CA3090812A1 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
CN113582975A (zh) 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
US9533059B2 (en) Peptide radiotracer compositions
WO2023098920A1 (zh) 一种双重靶向化合物及其制备方法和应用
CN115260160B (zh) 一种靶向成纤维细胞活化蛋白fap的化合物及其制备方法和应用
WO2024099245A1 (zh) 一种rgd二聚体化合物及其制备方法和应用
CA2129033A1 (en) Radiolabelled peptide compounds
JP2022529007A (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
WO2022170732A1 (zh) 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN115505032A (zh) 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法和应用
CN116751259A (zh) 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法
US8454936B2 (en) Metal chelators and methods of their use
CN116217505A (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
CN118119581A (zh) 放射性药物、其生产方法以及在疾病治疗、诊断和成像中的用途
WO2014096191A1 (en) Bis 2h-imidazole-2-thione chelating agents as ligands for radiopharmaceutical in vivo imaging
WO2024026072A1 (en) Fibroblast activation protein-targeted compositions and methods of use thereof
TW202327665A (zh) 基於肽的新型診斷劑和治療劑

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21925385

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2021427618

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2023531665

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2021925385

Country of ref document: EP

Effective date: 20230511

ENP Entry into the national phase

Ref document number: 2021427618

Country of ref document: AU

Date of ref document: 20210711

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 803235

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 3210863

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2023131649

Country of ref document: RU